Provided by Tiger Fintech (Singapore) Pte. Ltd.

HANSOH PHARMA

19.320
+0.3001.58%
Volume:3.83M
Turnover:74.13M
Market Cap:114.68B
PE:32.55
High:19.560
Open:19.420
Low:19.180
Close:19.020
Loading ...

Chinese Regulator Accepts Second BLA for Anti-Inflammatory Drug Licensed by Hansoh Pharmaceutical

MT Newswires Live
·
Yesterday

BRIEF-Hansoh Pharmaceutical Says Second Biologics License Application Of Xinyue Accepted By NMPA

Reuters
·
04 Mar

Hansoh Pharmaceutical - Second Biologics License Application of Xinyue Accepted by Nmpa

THOMSON REUTERS
·
04 Mar

Earnings are growing at Hansoh Pharmaceutical Group (HKG:3692) but shareholders still don't like its prospects

Simply Wall St.
·
03 Mar

Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$18.36 From HK$17.95, Keeps at Neutral

MT Newswires Live
·
26 Feb

Hansoh Pharmaceutical Group's Anti-Hives Capsule Obtains Chinese Regulator's Approval for Clinical Trials

MT Newswires Live
·
25 Feb

Chinese Regulator Designates Hansoh Pharmaceutical Group's Injection as Breakthrough-Therapy Drug for Bone Cancer

MT Newswires Live
·
25 Feb

BRIEF-Hansoh Pharmaceutical Says NMPA Granted Approval For HS-20093

Reuters
·
25 Feb

BRIEF-Hansoh Pharmaceutical Receives Clinical Trial Approval For Hs-10561 Capsules Issued By NMPA

Reuters
·
25 Feb

Hansoh Pharmaceutical - Nmpa Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093

THOMSON REUTERS
·
25 Feb

Hansoh Pharmaceutical - Clinical Trial Approval for Hs-10561 Capsules Issued by Nmpa

THOMSON REUTERS
·
25 Feb

Hansoh Pharmaceutical Says IgG4-Related Disease Drug Gets Priority Review from China Regulator

MT Newswires Live
·
10 Feb

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Simply Wall St.
·
10 Feb

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

Dow Jones
·
07 Feb

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Simply Wall St.
·
19 Jan

BRIEF-Hansoh Pharmaceutical Says HS-20093 Received FDA Breakthrough Therapy Designation Refractory Osteosarcoma

Reuters
·
07 Jan